Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by indaknownewfieon Mar 02, 2021 6:45pm
222 Views
Post# 32698585

CMAX - Study on Nasal Spray/ antiviral

CMAX - Study on Nasal Spray/ antiviralCMAX Clinical Research centre on North Terrace, Adelaide, increased its inpatient beds to 55 in 2020. CMAX Clinical Research centre, one of Australia’s largest and most experienced, on North Terrace, Adelaide, saw an unprecedented demand for medical clinical trials during the 2020 Covid pandemic. Established in 1993, CMAX specialised in  early-phase and first-time-in-human trials and initiated about 50 trials in 2020. This added to the 600 trials, including more than 100 first-time-in-human studies, for national and international clints from pharmaceutical, biotechnology and medical device companies. Three trials in 2002 looked at treatment options for Covid-19, including a nasal spray and a novel antiviral treatment. CMAX employed 200 staff in 2020 at its new purpose-built centre on North Terrace opposite the Royal Adelaide Hospital (where it was originally located) and Adelaide BioMed City, one of the largest health and life sciences clusters in the southern hemisphere. CMAX, as Adelaide BioMed City's clinical trials unit, was contributing to creating the next generation of medical technologies and medicines. CMAX staff numbers had almost doubled in the previous three years and it was looking to expand in 2021 with inpatient beds up to 55. Attracting more volunteers to take part in the growing clinical trial space was also a priority. Also in 2020, CMAX launched Fusion clinical research allowing health professionals to provide clinical trials in general practitioners’ (GPs) clinics. A dedicated team from CMAX would connect pharmaceutical, biotech, digital health and clinical research organisations to GPs and their patients who were keen to take part in clinical trial research within a GP clinic. This was expected to transform clinical medical trials to be done in new community settings. From 2002, CMAX became part of IDT Australia Limited that had partnered with the I'rom Group since 2012. In 2016, the I'rom Group bought CMAX shares and welcomed it into that group. 
<< Previous
Bullboard Posts
Next >>